FLT3 and acute myeloid leukemia: In recent years, the FDA has successively approved multiple small-molecule targeting inhibitors to treat AML, such as the Bcl-2-selective inhibitor venetoclax, the FLT-3 inhibitor midostaurin and gilteritinib [48].